Related Experiment Video

Updated: May 12, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.2K

Serum Malondialdehyde-Modified Low-Density Lipoprotein as a Risk Marker for Peripheral Arterial Stiffness in

Wei-Nung Liu1,2,3, Yi-Chiung Hsu2, Chia-Wen Lu1,4

  • 1Department of Medicine, Hualien Armed Forces General Hospital, Hualien 97144, Taiwan.

Medicina (Kaunas, Lithuania)
|May 25, 2024
PubMed

Insights

Higher levels of malondialdehyde-modified low-density lipoprotein (MDA-LDL), an oxidative stress marker, are linked to peripheral arterial stiffness (PAS) in hemodialysis patients. A serum MDA-LDL level of 80.91 mg/dL is identified as a key predictor of PAS.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Peripheral arterial stiffness (PAS), measured by brachial-ankle pulse wave velocity (baPWV), is a significant cardiovascular disease (CVD) biomarker in hemodialysis (HD) patients.
  • Malondialdehyde-modified low-density lipoprotein (MDA-LDL) is an oxidative stress marker associated with atherosclerosis and CVD.

Purpose of the Study:

  • To investigate the association between serum MDA-LDL and PAS in HD patients.
  • To determine the optimal cutoff value of serum MDA-LDL for predicting PAS.

Main Methods:

  • Cross-sectional study of 100 HD patients.
  • Serum MDA-LDL quantified by ELISA; baPWV measured by volume plethysmography.
  • Multivariable logistic regression and ROC curve analysis used to assess associations and identify cutoff values.

Main Results:

  • Higher serum MDA-LDL, older age, and elevated C-reactive protein were independently associated with PAS (ORs: 1.014, 1.044, 3.697, respectively).
  • The optimal MDA-LDL cutoff for predicting PAS was 80.91 mg/dL, with 79.25% sensitivity and 59.57% specificity.

Conclusions:

  • Elevated serum MDA-LDL levels (≥80.91 mg/dL) are independently associated with PAS in HD patients.
  • Oxidative stress, indicated by MDA-LDL, is implicated in PAS development.
  • Targeting MDA-LDL may offer a therapeutic strategy to mitigate cardiovascular risk in HD patients.

Keywords:
cardiovascular diseaseend-stage renal diseasehemodialysismalondialdehyde-modified low-density lipoproteinperipheral arterial stiffnesspulse wave velocity

More Related Videos

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis04:36

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis

Published on: October 2, 2020

2.2K
A Murine Model of Hemodialysis Access-Related Hand Dysfunction08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

1.7K

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...